AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A pharmaceutical composition comprising a mixture of:

(a) an active macromolecular principle which is a polypeptide or protein, polynucleotide or polysaccharide;

(b) a non-conjugated bile acid or salt; and

(c) an additive chosen from

(i) propyl gallate or a linear or branched chain C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylthio or C_{2-12} alkenyl ester of gallic acid which is optionally substituted with one or more groups which are the same or different and are selected from halogen and linear or branched chain C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylthio or C_{2-12} alkenyl;

(ii) butyl hydroxy anisole, or hydroxy anisole wherein the methoxy group linked to the aromatic ring and/or the hydrogen *ortho* to the hydroxyl group is/are replaced by one or more groups which are the same or different and are selected from linear or branched chain C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylthio and C_{2-12} alkenyl, either unsubstituted or substituted in any position by one or more halogen atoms; and

(iii) a mixture of (i) and (ii)

wherein the mixture comprises at least 1% by weight of the additive (c), wherein the ratio by weight of the non-conjugated bile salt + additive (b+c) to the active macromolecular principle is at least 3:1 and wherein the composition, when introduced into the intestine, does not raise the pH of the intestinal fluid above pH 7.5.